No Data
No Data
Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment
Ainos (AIMD) said Wednesday it is set to begin a clinical trial of a potential Veldona-based treatment for chronic gingivostomatitis in cats. Ainos described feline chronic gingivostomatitis as a chro
Ainos To Initiate Clinical Study Of New VELDONA-Based Animal Drug, Expanding Potential Market
Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synt
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
Current research suggests that FCGS results from multiple factors, including dental diseases, viral and bacterial pathogens, and environmental conditions, with a reported prevalence ranging between 0.7% and 12%.
Ainos Q1 2024 EPS $(0.57) Up From $(0.63) YoY; Revenue $20.729K Down From $49.164K YoY
Ainos Q1 2024 EPS $(0.57) Up From $(0.63) YoY; Revenue $20.729K Down From $49.164K YoY
10-Q: Quarterly report
Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729
04:13 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729
No Data
Ceegie : What should we expect on this one?
TrytosaveabitOP Ceegie: Not sure yet? Got to dig a bit deeper! But I see it as a positive! NFA If you need a deeper understanding Google 13D INVESTOPEDIA! You will get more information there than I can type! Hehehe GL
Jaguar8 TrytosaveabitOP: